Antiplatelet therapy for STEMI

Slides:



Advertisements
Similar presentations
August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
Advertisements

Unstable angina and NSTEMI
Treatment of Acute Coronary Syndrome with ST elevation ESC guidelines 2008 Dr. David Tran A&E dept. FVH 22/12/09.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
The Macstrak Project CCU Case Studies The following is a series of case studies to review different patient types and how they are captured on the form.
North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.
MANAGING ANGINA JIM McLENACHAN, CONSULTANT CARDIOLOGIST, LEEDS. 17 th November 2011.
Antiplatelet therapy in CAD MINILECTURE. Objectives Indications for Antiplatelet Therapy in patients with CAD and ACS Antiplatelet Therapy in the role.
ACUTE CORONARY SYNDROME (ACS). ACS Pathophysiology is that of a ruptured or eroded atheromatous plaque. Pathophysiology is that of a ruptured or eroded.
Management of Stable Angina SIGN 96
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association.
ACS and Thrombosis in the Emergency Setting
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Clopidogrel Audit Vikas Jasoria December What is it? Clopidogrel is a thienopyridine antiplatelet drug which reduces platelet aggregation by inhibiting.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
PRODIGY Objective Study Design Primary Composite Endpoint
Acute Coronary Syndromes. Learning outcomes To understand the clinical spectrum of coronary disease To recognise different presentations of the disease.
Acute Coronary Syndromes in West Hertfordshire Masood Khan.
CV Update – Guidelines & Debates Royal Pharmaceutical Society, Great Britain Barnet – 27/01/09 Dr Ameet Bakhai, FRCP – Cardiologist, Clinical Trials, Health.
Cooling Off? Early Intervention? Very Early Intervention? Steve Holmberg Sussex Cardiac Centre.
The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2:ARMYDA-2:
Cardiac update for GPs - Chest pain/angina Sanjay Sastry Consultant Cardiologist Royal Bolton Hospital Royal Bolton Hospital Manchester Heart Centre Wigan.
Support for implementing NICE guidance: Unstable angina and NSTEMI Unstable angina and NSTEMI, CG94, rd Edition March 2014.
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.
Chest Pain in the Emergency Department Junior Teaching C. Brown August 2015.
Acute Coronary Syndrome: In Hospital Antiplatelet Management
수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC Guideline for the Management of Patients.
Acute Coronary Syndrome
Use of OCT in Determining Dual Antiplatelet Treatment Duration
Cardiac causes of cardiac arrest
The Primary and Secondary Prevention of Cardiovascular Disease
Cangrelor Case Presentations
Disclosures Speaker’s bureau: Research support: Consulting: Equity
Stent Thrombosis and Optimal Duration of DAPT
Coronary artery disease
Volume 81, Issue 10, Pages (October 2010)
Randomisation before planned PCI with DES (n=2500)
T1: ACS Treatment Tutoring
T1: Post ACS Treatment Tutoring
Management of ST-Elevation Myocardial Infarction
The European Society of Cardiology Presented by Dr. Saman Rasoul
Ischaemic Heart Disease Acute Coronary Syndrome
Coronary artery disease
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Preventing Thrombotic Complications in ACS: State of the Art
Oral Anticoagulation and Preventing Stent Thrombosis
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
Unstable Angina and Non–ST Elevation Myocardial Infarction
Glenn N. Levine et al. JACC 2016;68:
Introduction Antiplatelet Agents ADP Receptor Antagonists.
Antiplatelet Therapy and Secondary Prevention
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Section A: Introduction
European Heart Association Journal 2007 April
NOACS: Emerging data in ACS/IHD
Section F: Clinical guidelines
Orlando, March , American College of Cardiology
Impact of Platelet Reactivity Following Clopidogrel Administration
Acute Coronary Syndrome (1)
What oral antiplatelet therapy would you choose?
Intermediate/low-risk UA
Nat. Rev. Cardiol. doi: /nrcardio
Roberta Rossini et al. JCIN 2018;11:
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
ESC Guideline on the Management of STEMI Recommendation for DAPT
Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.
Section C: Clinical trial update: Oral antiplatelet therapy
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
Presentation transcript:

Antiplatelet therapy for STEMI Confirm diagnosis: ST elevation MI LBBB with classical history Fax ECG to infarct centre co-ordinator to arrange immediate primary PCI Confirm diagnosis: ST elevation MI LBBB with classical history Fax ECG to infarct centre co-ordinator to arrange immediate primary PCI Give Aspirin 300mg loading dose/75 mg daily indefinitely, unless contraindicated. If patient over 75, consider coprescription of PPI Give ticagrelor 180mg loading dose (or prasugrel 60mg loading dose) unless contraindicated Immediate PPCI in regional centre Discharge on antiplatelet therapy for 12 months as standard treatment. If patient presents with side effects of antiplatelet therapy contact the responsible consultant cardiologist Selected patients at high risk may be offered clopidogrel 75mg or ticagrelor 60mg bd, for a maximum of three years Selected patients at low risk may be switched from prasugrel/ticagrelor to clopidogrel 75mg one month post MI, for a further 11 months. Notes PPI (proton pump inhibition) should be considered to reduce bleeding risk in older patients on Aspirin. Patients for prolonged antiplatelet use or for earlier switching to clopidogrel should be selected for these alternatives on a case by case basis by the responsible interventional consultant only. Antiplatelet therapy for late presenting STEMI should be same as for those having PPCI. Creatinine levels should be checked within a month after starting ticagrelor Antiplatelets should not be interrupted without prior discussion the responsible consultant cardiologist Patients on warfarin or NOAC should generally be treated in accordance with NICE guidance CG172 NECVN Consensus, July 2017, v 3.2

Antiplatelet therapy in NSTEMI or unstable angina (UA) Make diagnosis: NSTEMI - suggestive history and raised biomarkers (hs troponin preferred) UA - suggestive history and either ongoing chest pain, ECG changes, positive stress test or GRACE risk>1.5% Give Aspirin 300mg loading dose/75 mg daily indefinitely, unless contraindicated. If patient over 75, consider coprescription of PPI Give clopidogrel 600mg loading dose and 75mg daily Review by cardiologist - diagnosis confirmed? YES NO Discontinue clopidogrel Load with ticagrelor 180mg and 90mg b.d. for 12 months, as standard therapy Review need for DAPT, consider alternative diagnosis Selected patients at high risk may be offered clopidogrel 75mg or ticagrelor 60mg bd, for up to three years Selected patients at low risk, or if intolerant to ticagrelor/prasugrel, may switch to clopidogrel 75mg one month post MI, for a further 11 months. Use 300mg loading dose. Notes PPI (proton pump inhibition) should be considered to reduce bleeding risk in older patients on Aspirin. Patients for prolonged antiplatelet use or for earlier switching to clopidogrel should be selected for these alternatives on a case by case basis by the responsible interventional consultant only. Antiplatelets should not be interrupted without prior discussion with the responsible consultant cardiologist Creatinine levels should be checked within a month after starting ticagrelor Aspirin/clopidogrel/rivaroxaban and Aspirin/prasugrel are alternative NICE-approved options in NSTEMI. Patients on warfarin or NOAC should generally be treated in accordance with NICE guidance CG172 NECVN Consensus, July 2017, v3.2